More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

Collaboration on Renal Cancer Imaging for Japanese market

Aug 15, 2018 at 10:42 PM EDT · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Aug 15, 2018 at 10:42 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/collaboration-on-renal-cancer-imaging-for-japanese-market

Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20↗

Telix Pharmaceuticals Limited on 6ix

Story so far

  • TLX and JFE progress Japanese manufacturing partnershipJul 26, 2018
  • Telix establishes Japanese subsidiaryJan 15, 2018

Earlier from Telix Pharmaceuticals

  • Telix JV Entity Extends Contract with Endocyte to Include EUAug 9, 2018
  • Telix receives $55m Overseas FindingAug 2, 2018
  • Appendix 4C - June 2018 QuarterJul 26, 2018
  • TLX and JFE progress Japanese manufacturing partnershipJul 25, 2018
  • Prostate imaging regulatory update - FDA review of DMFJul 24, 2018

Later from Telix Pharmaceuticals

  • Telix files Ph III trial for Kidney Cancer Imaging in EuropeAug 22, 2018
  • Half Yearly Report and AccountsAug 30, 2018
  • TLX receives ethics approval to commence Glioblastoma StudySep 3, 2018
  • Telix completes acquisition of Atlab PharmaSep 10, 2018
  • Strategic Collaboration Agreement with GenesisCareOct 9, 2018
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer